ERBB2 and neoplasm: The SPECT and biodistribution studies (Figure 8) of the cleavable radioimmunoconjugate in the HER2+ NIH3T6.7 tumor xenografts revealed a 35% improvement in blood clearance, while that in other normal organs remained comparable.